In this online, self-learning activity:
Narcolepsy is a neurologic disorder characterized by inappropriate regulation of the sleep-wake cycle and excessive sleepiness during waking hours. Affected individuals may fall asleep at inappropriate times, such as when talking to others, eating, or even driving. Roughly 135,000 to 200,000 people in the United States are estimated to have narcolepsy. Women and men are affected by narcolepsy equally, and most patients begin having symptoms between the ages of 7 and 25 years. The treatment of narcolepsy may be complicated and must be tailored individually after careful evaluation of the patient’s symptoms.
The following HCPs: neurologists, internists, PCPs, psychiatrists; nurse practitioners, physician assistants, and pharmacists who specialize in the aforementioned areas of specialty; and those who otherwise commonly care for or clinically encounter patients with sleep disorders.
Commercial Support Disclosure: This program is supported by educational grants from Harmony Biosciences and Jazz Pharmaceuticals.
This activity is free of charge.
Release Date: March 22, 2023 -- Expiration Date: March 22, 2025
Faculty: Alon Avidan, M.D., MPH, FAASM, FAAN
Faculty introduction, disclosures |
Introductory content: review of narcolepsy
|
Screening, diagnosis, and treatment of narcolepsy
|
Summary, conclusions, and best practice recap |
By the end of the session the participant will be able to:
ACCME Activity #202396752
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.
Disclosure of Faculty: Alon Y. Avidan, MD, MPH, FAASM, FAAN, Director, UCLA Sleep Disorders Center, David Geffen School of Medicine at UCLA, has received financial compensation for consulting work and/or speakers bureau from Merck, Idorsia, Takeda, Harmony and Eisai.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.
Faculty WILL NOT discuss off-label uses.
All relevant financial relationships have been mitigated.
ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Commercial Support Disclosure: This program is supported by educational grants from Harmony Biosciences and Jazz Pharmaceuticals.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Insomnia: Updates from SLEEP 2022, (the 36th annual meeting of the APSS)